Abstract
Immunostimulatory DNA sequences (ISS) contain unmethylated CpG dinucleotides within a defined motif. Immunization with ISS-based vaccines has been shown to induce high antigen-specific cytotoxic lymphocyte (CTL) activity and a Th1-biased immune response. We have developed a novel ISS-based vaccine composed of ovalbumin (OVA) chemically conjugated to ISS–oligodeoxynucleotide (ODN). Protein–ISS conjugate (PIC) is more potent in priming CTL activity and Th1-biased immunity than other ISS-based vaccines. Cytotoxic lymphocyte activation by ISS–ODN-based vaccines is preserved in both CD4−/− and MHC class II−/− gene-deficient animals. Furthermore, PIC provides protection against a lethal burden of OVA-expressing tumor cells in a CD8+ cell-dependent manner. These results demonstrate that PIC acts through two unique mechanisms: T-helper-independent activation of CTL and facilitation of exogenous antigen presentation on MHC class I. This technology may have clinical applications in cancer therapy and in stimulating host defense in AIDS and chronic immunosuppression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Carson, D. & Raz, E. Oligonucleotide adjuvants for T helper 1 Th1 -specific vaccination. J. Exp. Med. 186, 1621–1622. (1997).
Krieg, A.M., Yi, A.K., Schorr, J. & Davis, H.L. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 6, 23–27 (1998).
Shimada, S. et al. Antitumor activity of the deoxyribonucleic acid fraction of Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors. J. Natl. Cancer Inst. 74, 681–688 (1985).
Tokunaga, T. et al. Antitumor activity of the deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72, 955–962 (1984).
Yamamoto, S. et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity. J. Immunol. 148, 4072–4076 (1992).
Martin-Orozco, E. et al. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int. Immunol. 11, 1111–1118 ( 1999).
Krieg, A.M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549 ( 1995).
Lipford, G.B. et al. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27, 2340–2344 (1997).
Sato, Y. et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273, 352–354 (1996).
Corr, M., Lee, D.J., Carson, D.A. & Tighe, H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 184, 1555–1560. ( 1996).
Roman, M. et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3, 849–854 (1997).
Horner, A.A. et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell. Immunol. 190, 77–82 ( 1998).
Chu, R.S., Targoni, O.S., Krieg, A.M., Lehmann, P.V. & Harding, C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 Th1 immunity. J. Exp. Med. 186, 1623–1631 ( 1997).
Davis, H.L. et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870–876 (1998).
Keene, J.-A. & Foreman, J. Helper activity is required for the in vivo generation of cytotoxic lymphocytes. J. Exp. Med. 155, 768–782 (1982).
Mitchison, N.A. & O' Malley, C. Three-cell-type cluster of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response. Eur. J. Immunol. 17, 1579–1583 (1987).
Bennett, S.R.M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 393, 478–480 (1998).
Ridge, J.P., Di Rosa, F. & Matzinger, P. A conditioned dendritic cell can be a bridge between CD4+ T-helper and a T-killer cell. Nature 393, 474–478 (1998).
Schoenberger, S.P., Toes, R.E.M., van der Voort, E.I.H., Offringa, R. & Melief, C.J.M. T-cell help for cytotoxic lymphocytes is mediated by CD40–CD40L interactions. Nature 393, 480–483 (1998).
Lin, M.S. & Chen, Y.W. B cell differentiation. II. Isotype potential of a single B cell. Cell. Immunol. 150, 343–352 (1993).
Porgador, A., Snyder, D. & Gilboa, E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156, 2918– 2926 (1996).
Lanzavecchia, A. License to kill. Nature 393, 413– 414 (1998).
Harding, F.A. & Allison, J.P. CD28–B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177, 1791 –1796 (1993).
Grewal, I.S. & Flavell, R.A. The role of CD40 ligand in costimulation and T-cell activation. Immunol. Rev. 153, 85–106 (1996).
Sigal, L.J., Reiser, H. & Rock, K.L. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo. J. Immunol. 161, 2740–2745 (1998).
Trinchieri, G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann. Rev. Immunol. 13, 251–276 (1995).
Jakob, T., Walker, P.S., Krieg, A.M., Udey, M.C. & Vogel, J.C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol. 161, 3042–3046 (1998).
Kovacsovics-Bankowski, M. & Rock, K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267, 243–246 ( 1995).
Shen, Z., Reznikoff, G., Dranoff, G. & Rock, K. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158, 2723– 2730 (1997).
Reis e Souza, C. & Germain, R.N. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182, 841–851 (1995).
Pfeifer, J.D. et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 359–362 (1993).
Gromme, M. et al. Recycling MHC class I molecules and endosomal peptide loading. Proc. Natl. Acad. Sci. USA 96, 10326– 10331 (1999).
Reiss, M. Transforming growth factor-beta and cancer: a love–hate relationship? Oncol. Res. 9, 447–457 (1997).
Botti, C., Seregni, E., Ferrari, L., Martinetti, A. & Bombardieri, E. Immunosuppressive factors: role in cancer development and progression. Int. J. Biol. Markers 13, 51–69 (1998).
Korkolopoulous, P., Kaklamanis, L., Pezzella, F., Harris, A.L. & Gatter, K.C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Brit. J. Cancer 73, 148–153 (1996).
Seliger, B. et al. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp. Hematol. 24, 1275–1279 ( 1996).
Dejardin, E. et al. Regulation of major histocompatibility complex class I expression by NF-kappaB-related proteins in breast cancer cells. Oncogene 16, 3299–3307 ( 1998).
Acknowledgements
The authors wish to thank Tomoko Hayashi, Yucan Chiu, and Nadya Cinman for expert technical assistance, and Nancy Noon and Jane Uhle for editorial assistance. We also thank Wei Ping Feung-Leung and Tak Mak for the generous gift of CD8−/− mice, and Angel Porgador and Eli Gilboa for the generous gift of the E.G7–OVA cell line. This work was supported in part by grants from the National Institutes of Health (AI 40682, AI 47078, and AR 44850) and by Dynavax Technologies. H.J.C. is supported by a research resident fellowship from the Sam and Rose Stein Institute for Research on Aging (La Jolla, CA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cho, H., Takabayashi, K., Cheng, PM. et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 18, 509–514 (2000). https://doi.org/10.1038/75365
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/75365
This article is cited by
-
Site-specific antigen-adjuvant conjugation using cell-free protein synthesis enhances antigen presentation and CD8+ T-cell response
Scientific Reports (2021)
-
A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model
Journal of Translational Medicine (2020)
-
A facile approach to enhance antigen response for personalized cancer vaccination
Nature Materials (2018)
-
Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines
Scientific Reports (2015)
-
Dendritic cell-targeted vaccines — hope or hype?
Nature Reviews Immunology (2014)